Skip to main content Accessibility help
×
Home
Hostname: page-component-768ffcd9cc-5rkl9 Total loading time: 1.646 Render date: 2022-12-03T05:08:15.086Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions[Opens in a new window]

Abstract

Cardiac safety of antipsychotic drugs continues to be a concern for both typical and atypical antipsychotics. Risk appears greatest in those with pre-existing cardiac disease but many patients may have occult cardiovascular disease. In addition, several drugs appear to increase the likelihood of diabetes and weight gain, which may have an additive adverse effect. On the basis of risk of sudden cardiac death and risk of QTc prolongation we suggest considering antipsychotics in two categories – higher and lower risk. Of most concern is the use of large cumulative doses of antipsychotics that are sometimes given inadvertently by different prescribers. Clinicians need to be aware how to read an ECG, and how to monitor physical parameters and interpret the significance of QTc prolongation in relation to antipsychotic prescribing. We suggest provisional guidance on antipsychotic monitoring in relation to cardiac safety but acknowledge that future studies will help clarify which antipsychotic drugs and which concomitant risk factors are most important for those with and without established cardiac disease.

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 2006 

The remit of antipsychotic medication has expanded beyond the treatment of schizophrenia and related psychosis into many other areas, including bipolar affective disorders, psychotic and treatment-resistant depression, dementia and delirium (Reference Kupfer and SartoriusKupfer & Sartorius, 2002). Recent advances have led to the suggestion that first-line treatment for schizophrenia should include atypical antipsychotics, but these drugs cannot be assumed to be equally safe (Table 1) or, indeed, equally effective. One area that is important for all psychotropic drugs is their cardiac safety (Box 1). Some sources caution against the use of butyrophenones such as haloperidol (Royal Australian and New Zealand College of Psychiatrists, 2005), others are more concerned with thioxanthenes such as thioridazine (Griffiths & Flannagan, 2005), whereas others caution against intravenous administration (National Institute for Clinical Excellence, 2002). These recommendations, regardless of their evidence base, will have considerable effect on the emergency, acute and maintenance use of antipsychotics (Reference Bateman, Good and AfshariBateman et al, 2003).

Table 1 Classification of antipsychotic medication in terms of risk of cardiac arrhythmias

Drug Chemical structure Risk of cardiac arrhythmias
Typical antipsychotics
    Chlorpromazine Aliphatic phenothiazine Higher
    Pimozide Diphenylbutylpiperidine Higher
    Thioridazine Piperidine Higher
    Trifluoperazine Piperazine Lower
    Haloperidol Butyrophenone Lower
    Sulpiride1 Substituted benzamide Lower
Atypical antipsychotics
    Clozapine Dibenzodiazepine Higher
    Quetiapine Dibenzothiazepine Lower
    Risperidone Benzisoxazole Lower
    Amisulpride Substituted benzamide Lower
    Olanzapine Thienobenzodiazepine Lower
    Zotepine Dibenzothiepine Lower

Box 1 Cardiovascular adverse effects of anti-psychotic drugs

Common

Orthostatic (postural) hypotension

Syncope

Rare

Reduced heart rate variability

Prolongation of the QT/QTc intervals

Widened QRS complex

Very rare

Ventricular tachycardia

Torsades de pointes

Myocarditis

Cardiomyopathy

Pericarditis

Cardiac arrest and sudden cardiac death

There is now unequivocal evidence that many typical antipsychotics increase the risk of ventricular arrhythmias and cardiac arrest (Reference Ray, Meredith and ThapaRay et al, 2001; Reference Liperoti, Gambassi and LapaneLiperoti et al, 2005). Evidence to date also supports an association between many atypical antipsychotic drugs and the occurrence of unexplained sudden death (see Part 1 of this overview: Reference Abdelmawla and MitchellAbdelmawla & Mitchell, 2006).

Clinicians must be aware of the factors that influence cardiac safety in patients prescribed antipsychotics. Of at least equal importance, they must be able sensibly to choose for each patient an antipsychotic agent with minimal iatrogenic adverse effects and to monitor patients during treatment. We will look at each of these in turn.

Can clinicians estimate the risk of serious adverse events?

Differences between antipsychotics

Available evidence does not yet allow accurate comparison of the quantitative risk of serious cardiovascular side-effects or sudden cardiac death for all antipsychotics, not least because several agents have not been examined in sufficient detail. Nevertheless, an elevated risk of serious adverse cardiac events or sudden cardiac death has been documented for thioridazine, clozapine, droperidol, pimozide, pipamperone and sertindole. We suggest that these are considered higher-risk antipsychotics in terms of serious cardiac effects. Haloperidol, quetiapine, risperidone, chlorpromazine and trifluoperazine have a tendency to extend the QT interval even at therapeutic doses, but their link with sudden cardiac death is not yet clarified. Amisulpride, aripiprazole, olanzapine, sulpiride and zotepine have not been linked with an elevated risk of sudden cardiac death or QTc prolongation. In terms of sudden cardiac death these appear to be lower-risk antipsychotics. However, further data may change this suggested classification. For more information see Part 1 of this overview (Reference Abdelmawla and MitchellAbdelmawla & Mitchell, 2006).

Influence of moderating variables

A large number of variables influence the likelihood of antipsychotic-induced sudden death. The two most important are pre-existing heart disease and the total dose of antipsychotic that is bioavailable to the heart. Important types of heart disease linked with sudden cardiac death include ischaemia, dilated cardiomyopathy and left ventricular systolic dysfunction. Symptoms such as dyspnoea, syncope, dizziness, intermittent claudication and cognitive impairment should raise the suspicion of a systemic vascular disease and prompt investigations for heart disease (see below). Demographically, sudden cardiac death is more likely in elderly people and in women.

Evidence suggests that an increase in the bioavailable dose of antipsychotic medication rather than the route of administration or underlying condition is the most important drug-related variable (Reference Waddington, Youssef and KinsellaWaddington et al, 1998; Reference Hennessy, Bilker and KnaussHennessy et al, 2002). Factors that influence the total bioavailable dose include frequency of dosing and polypharmacy. In turn, polypharmacy and high dosing are influenced by the psychiatrist's attitudes, nurses’ requests for more drugs and, of course, the patient's clinical condition (Reference Diaz and de LeonDiaz & de Leon, 2002; Reference Ito, Koyama and HiguchiIto et al, 2005). Although it may be an oversimplification to rule out high-dose prescribing, clinicians must bear in mind a different balance of risk v. benefits in this case. Drug–drug interactions are widely considered to be important, and the clearest evidence for an increased risk relates to pharmacodynamic interactions (see ‘Drug interactions’ below).

Risk associated with rapid tranquillisation

There is an elevated risk of sudden collapse when antipsychotic medications are given during a period of high physiological arousal (Royal College of Psychiatrists, 1997). Some cases have involved serious cardiac events but rarely sudden cardiac death (Reference Jusic and LaderJusic & Lader, 1994). The mechanism is not fully understood, but one hypothesis is that physical restraint of the patient may inadvertently restrict breathing and cause greater cardiac strain, resulting in hypoxia and myocardial irritability. This suggests that the method of control and restraint is of key importance (Reference O'Brien and OyebodeO'Brien & Oyebode, 2003). We could find no evidence from carefully controlled studies that intravenous administration of antipsychotics is more dangerous than either the intramuscular route or oral dosing (Reference Santos, Beliles, Arana, Stoudemire and FogelSantos et al, 1998; Reference McAllister-Williams and FerrierMcAllister-Williams & Ferrier, 2002).

Patients requiring rapid tranquillisation should be closely monitored for clinical response, personal safety and adverse effects, and caution is advisable, particularly if repeated doses are given over a short period.

Cardiovascular screening of patients starting antipsychotics

Clinical history

A careful history will help elucidate any pre-existing cardiac disease, including heart failure, myocarditis, myocardial infarction and cardiac arrhythmias. One genetic syndrome is of note. The congenital long-QT syndrome (LQTS) predisposes to future serious cardiac events, and it may be indicated by recurrent syncope or a family history of early sudden death. Left ventricular hypertrophy, ischaemia and a low left ventricular ejection fraction are particular risk factors for sudden cardiac death and torsade de pointes (see Part 1: Reference Abdelmawla and MitchellAbdelmawla & Mitchell, 2006). A history of severe hepatic or renal impairment, eating disorder or any metabolic condition should be noted, as should significant alcohol or substance misuse. A detailed history of both psychotropic and non-psychotropic drug use will allow clarification of possible pharmacodynamic and pharmacokinetic interactions (see below).

Clinical investigations

We suggest that patients about to receive higher-risk antipsychotics or those known to have vulnerability should have a baseline electrocardiogram (ECG) before the medication is started. It is also important to consider the ECG recommendations in the data sheets of individual antipsychotics. Biochemical testing may reveal hypokalaemia and hypomagnesaemia, which are risk factors for significant prolongation of the QTc interval. If significant QTc interval prolongation is evident, serum electrolyte and magnesium levels should be measured. A cardiologist's opinion should be obtained if the patient reports recent cardiac ischaemia or significant abnormalities are suspected on an ECG.

Interpretation of the ECG

The QT interval is measured using the trace from lead II or from the lead on which the end of the T-wave is most clearly defined (Reference SchweitzerSchweitzer, 1992; Reference GarsonGarson, 1993). Measurement of the QT interval can be difficult if the T-waves are flat, broad or notched. For example, a notched T-wave could represent fusion of the T-wave and the U-wave. Consequently, machine-generated QTc data may have to be double-checked.

The QT interval should be adjusted for heart rate, which gives the QTc interval. The most commonly used method for this adjustment is Bazett's formula (Fig. 1), which is used in most automated devices (Reference BazettBazett, 1920; Reference Funk-Brentano and JaillonFunk-Brentano & Jaillon, 1993; Reference TaylorTaylor, 2003).

Fig. 1 An ECG trace showing the QT interval.

If the patient is taking medication that affects the QT interval, the time of measurement relative to the time at which the drug was administered may affect the duration of the interval, owing to variation in drug plasma levels. Optimally, the QT interval should be measured within 30–60 min of the peak plasma concentration (Reference Ames, Camm and CookAmes et al, 2002).

If an ECG is difficult to interpret the clinician should consider seeking a cardiologist's opinion.

Testosterone appears to reduce the QT interval, so mean QTc intervals are greater in women than in men after puberty (Reference Rautaharju, Zhou and WongRautaharju et al, 1992). Values generally accepted as indicating normal, short and prolonged QTc intervals vary for men and women, as shown in Table 2.

Table 2 QTc intervals

Duration, ms
Men Women
Short <430 <440
Borderline 430 to <450 440 to <460
Prolonged >450 >460

If the patient has a prolonged baseline QTc, it is important to try to avoid all QT-prolonging medications, including high-risk antipsychotics. If the QTc at baseline is short, routine clinical care is acceptable but with the normal cautions regarding non-cardiac adverse effects. There is an area of clinical uncertainty if the baseline ECG reveals a borderline QTc interval (between 430 and 450 ms in men and 440 and 460 ms in women). In such cases a repeat ECG is advised.

The Committee for Proprietary Medicinal Products (1997) advises that an increase in QTc of 60 ms or more above the drug-free baseline should raise concern. In cases where the QT interval increases between serial ECGs (QTc variability) enhanced clinical care is indicated. This involves avoiding drugs that could disturb the electrolyte balance or prolong the QT interval further and monitoring of cardiovascular, hepatic and renal function. Most importantly, a switch to a low-risk antipsychotic should be made if assessment of the clinical risks and benefits supports this. We also recommend that the cumulative dose of all antipsychotics received, including as-needed (PRN) medication, be carefully documented in chlorpromazine or haloperidol equivalents.

A QTc interval of 500 ms and above is widely accepted as indicating substantially higher risk of torsade de pointes (Reference BotsteinBotstein, 1993; Reference Welch and ChueWelch & Chue, 2000; Reference Glassman and BiggerGlassman & Bigger, 2001; Reference Malik and CammMalik & Camm, 2001).

Torsade de pointes is a malignant polymorphic ventricular tachyarrhythmia. It can be asymptomatic or it can manifest with dizziness, light headedness, nausea and vomiting, palpitations or syncope. On an ECG, torsade de pointes is characterised by QRS complexes of changing amplitude. It is usually a transient, self-correcting and reversible condition, but occasionally it leads to ventricular fibrillation that presents clinically as a cardiac arrest. About 1 in 10 torsade de pointes events leads to sudden death (Reference Montanez, Ruskin and HebertMontanez et al, 2004).

Torsade de pointes is largely unpredictable, but certain risk factors can be identified (see Part 1 of our overview) that are essentially the same as the risk factors for sudden cardiac death. The management of acute torsade de pointes includes withdrawal of any offending agents, empirical administration of magnesium irrespective of the serum magnesium level, correction of serum potassium to 4.5–5 mEq/l and interventions to increase heart rate (isoprenaline or pacing) if necessary.

Monitoring of physical health

All patients

Various guidelines have appeared on monitoring the physical health of people prescribed antipsychotics (Reference Marder, Essock and MillerMarder et al, 2004; Reference Taylor, Paton and KerwinTaylor et al, 2005). Caridac monitoring must be considered in the context of general health monitoring and, in particular, monitoring for metabolic disturbances.

Physicians should monitor potassium and, ideally, magnesium levels in patients who start QT-prolonging medications (Reference Al-Khatib, Allen LaPointe and KramerAl-Khatib et al, 2003). Hypokalaemia has been associated with many factors, including: diuretics, digoxin and corticosteroids; intensive exercise, wound drainage and burns; and stressful situations (Reference Hatta, Takahashi and NakamuraHatta et al, 1999). Drugs that have the potential to affect electrolyte balance (diuretics, β2 agonists, cisplatin, laxatives and corticosteroids) should be prescribed with caution. Hypomagnesaemia (Box 2) interferes with ventricular repolarisation.

Box 2 Common causes and signs of hypomagnesaemia

Causes

  1. Malnutrition

  2. Crohn's disease

  3. Treatment with diuretics or aminoglycoside antibiotics

  4. Transfusion of blood products preserved with citrate

  5. Alcohol misuse

  6. Hyperglycaemia

  7. Sepsis

  8. Alkalaemia

  9. Clinical signs

Signs

  1. Prolonged QT interval and broadening of the T-wave on ECG

  2. Muscle weakness

  3. Tremors

  4. Vertigo

  5. Ataxia

  6. Chvostek's and Trousseau's signs

  7. Generalised muscle spasticity

  8. Depression

  9. Psychosis

  10. Hypertension

  11. Dysphagia

  12. Anorexia

  13. Nausea

The Committee on Safety of Medicines and the Medicines Control Agency recommend that ECGs and electrolyte measurements be repeated after each dose escalation and at 6-monthly intervals (Medicines Control Agency & Committee on Safety of Medicines, 2001).

Patients with cardiovascular disease

The measures outlined in the previous section apply to all patients taking antipsychotics. Patients with established cardiovascular disease require enhanced monitoring of their physical health. As mentioned earlier, we suggest a minimum of a baseline ECG before they start antipsychotic medication. Routine measurement of weight, blood pressure and heart rate and random glucose tests may be supplemented with measurement of: fasting plasma glucose or haemoglobin A1c; total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol; and triglyceride levels. Patients with complex cardiac problems, those seen soon after a myocardial infarction and those in heart failure will need joint care with a cardiologist.

Drug interactions

The risk of cardiac arrhythmias and sudden death is not restricted to antipsychotic or even psychotropic drugs. Box 3 lists some other psychotropic and also non-psychotropic medications associated with QT prolongation and potentially serious cardiac arrhythmias. Clinicians are advised to check a standard reference such as the British National Formulary (BNF) for the effect on the QT interval of co-prescribed medications.

Box 3 Drugs associated with QT prolongation

Antiarrhythmics
Almokalant1
Amiodarone
Bepridil
Bretylium
Disopyramide
Dofetilide
Ibutilide1
Procainamide
Propafenone
Quinidine
Sotalol and d-sotalol1
Antibiotics
Clarithromycin
Clindamycin
Co-trimoxazole
Erythromycin
Fluconazole
Gatifloxacin
Levofloxacin
Moxifloxacin3
Pentamidine
Sparfloxacin3
Spiramycin
Antimalaria drugs
Chloroquine
Halofantrine
Mefloquine
Quinine
Antihistamines
Terfenadine3
Astemizole3
Migraine drugs
Sumatriptan
Zolmitriptan
Serotonin antagonists
Ketanserin1
Cisapride2
Antipsychotics
Thioridazine3
Pimozide3
Ziprasidone1
Sertindole3
Droperidol2
Haloperidol
Chlorpromazine
Risperidone
Olanzapine
Antidepressants
Amitriptyline
Clomipramine
Citalopram
Desipramine
Doxepin
Fluoxetine
Imipramine
Maprotiline
Nortriptyline
Paroxetine
Venlafaxine
Other psychotropics
Chloral hydrate
Lithium
Methadone
Others
Amantadine
Cyclosporin
Diphenylhydramine
Hydroxyzine
Tamoxifen
Vasopressin

Polypharmacy, be it with other psychotropic or with non-psychotropic drugs, should be rationalised. If needed, a clear clinical justification should be documented, including discussion with the patient and/or carer, particularly if the combination may result in additive ECG effects.

Polypharmacy is the most important source of pharmacokinetic and pharmacodynamic interactions. Torsade de pointes and QT prolongation have been reported with IKr channel blockers, the antihistamines terfenadine and astemizole, and cisapride (Reference Vitola, Vukanovic and RodenVitola et al, 1998), leading to licensing restrictions or revocation for some (Box 3). These drugs are metabolised by CYP 3A4 of the cytochrome P450 (CYP) system, but this metabolism can be inhibited by certain other drugs, including, for example, selective serotonin reuptake inhibitors (fluvoxamine, fluoxetine, sertraline) (Tables 35). Serious cardiac arrhythmias have been reported in patients taking certain antihistamines with drugs that inhibit CYP 3A4 (Reference Smith, Book, Fuster, Alexander and O'RourkeSmith & Book, 2004). Some women appear to metabolise these drugs slowly, and thus female gender is a risk factor for drug-induced arrhythmia (Reference PrioriPriori, 1998).

Table 3 Antipsychotic drugs and cytochrome P450 metabolising enzymes1

Cytochrome P450 (CYP) enzymes
CYP 1A2 CYP 2D6 CYP 2C9 CYP 2C19 CYP 3A4
Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor
Clozapine
Haloperidol
Thioridazine
Haloperidol
Chlorpromazine
Zuclopenthixol
Risperidone
Sertindole
Clozapine
Thioridazine
Haloperidol
Clozapine (?) Risperidone
Quetiapine
Pimozide

Adverse outcomes when drugs are co-prescribed will also depend on whether a drug has a single or multiple metabolic pathways.

Conclusions

Figure 2 summarises the guidance we have given on monitoring patients prescribed antipsychotics. Psychiatrists should be aware of the possible adverse cardiac effects of these drugs on people with pre-existing cardiac disease or cardiac risk factors. Unfortunately, these are particularly common in people with schizophrenia. In addition, obesity, hyperlipidaemia and glucose intolerance may be exacerbated by antipsychotic drug therapy (Reference Abidi and BhaskaraAbidi & Bhaskara, 2003). This suggests that cardiac safety should be a routine part of clinical care. The advice given here constitutes a preventive strategy that is likely to be worthwhile even if the absolute risk of serious cardiac events is low. Attention should be paid to the general physical health of people with serious mental illnesses, with a full screening for modifiable cardiovascular risk factors.

Fig. 2 Clinician's guide to antipsychotic monitoring in relation to cardiovascular disease.

High-dose prescribing

High-dose prescribing of single or multiple anti-psychotics is a concern that has been previously highlighted. In a US study of people with established schizophrenia treated in the community, Reference Ganguly, Kotzan and MillerGanguly et al(2004) found the prevalence of short-term polypharmacy to be about 40% and of long-term polypharmacy about 25%. However, in a revised consensus statement the Royal College of Psychiatrists suggests that there are some justifiable cases of temporary polypharmacy (such as when changing drugs and in treatment-resistant cases) (Royal College of Psychiatrists, 2006). A full discussion of the possible clinical indications for polypharmacy is beyond the scope of this article (see Reference Haw and StubbsHaw & Stubbs, 2003), and we simply point out that there is an additional risk with this strategy and therefore particular care should underlie such treatment decisions.

Drug choice

The choice of antipsychotic is important in determining risk. In Fig. 2 we have grouped antipsychotics into two categories. The use of drugs with more pronounced effects on cardiac repolarisation can be justified only if the drug has specific advantages for the patient. Such risk–benefit decisions can be difficult and, where possible, the patient should be involved in an informed discussion.

Cumulative dosing

Clinicians should be particularly aware that high doses of antipsychotics, often in combination and from multiple prescribers, can accumulate over a number of days or weeks. A national audit of the prescribing of antipsychotic drugs in 47 UK mental health services (Reference Harrington, Lelliott and PatonHarrington et al, 2002) showed that, of 3132 patients, 20% were prescribed a total dose of antipsychotic medication above that recommended by the BNF. In the majority of cases, notes failed to record an indication for high-dose prescribing or that the patient had been informed. Only 8% had undergone an ECG, and 48% were prescribed more than one antipsychotic. A separate audit of drug-prescribing habits showed that polypharmacy was the most likely reason for receiving a high dose (Reference Lelliott, Paton and HarringtonLelliott et al, 2002). Factors that influenced the probability of polypharmacy were younger age, male gender, detention under the Mental Health Act 1983 and a diagnosis of schizophrenia. Clinician-related preferences are also a significant factor in polypharmacy (Reference Wilkie, Preston and WesbyWilkie et al, 2001).

Training needs

One important implication of these issues is the need for training. A survey of junior doctors in psychiatry in the UK demonstrated that less than 20% were able to identify a prolonged QTc interval on an ECG (Reference Warner, Gledhill and ConnellWarner et al, 1996). A more recent survey of healthcare practitioners (including psychiatrists and other physicians) in the USA showed that 61% of respondents could identify the QT interval on an ECG but only 36% correctly measured it (Reference Allen LaPointe, Al-Khatib and KramerAllen LaPointe et al, 2002). Clearly it is impractical to refer every patient to a cardiologist for QT-interval measurement, just as it is inappropriate to expect psychiatrists to measure every person's depressive symptoms. Therefore healthcare professionals involved in the care of people with mental illnesses (in particular psychiatrists and general practitioners) ideally must learn how to measure the QT interval and/or arrange access to an automatic ECG machine. This could form part of the periodic training in cardiopulmonary resuscitation for hospital staff recommended by the Royal College of Psychiatrists (1997).

Several typical and atypical antipsychotics carry a higher than average risk of QTc prolongation and sudden cardiac death. Although the absolute risk is small, appropriate awareness of this risk will help to keep the number of antipsychotic-induced sudden deaths to a minimum.

Declaration of interest

None.

MCQs

  1. 1 As regards measurement of the QTc interval:

    1. a it is less difficult when the T-waves are flat

    2. b ideally an ECG should be performed 12 h after the administration of the antipsychotic

    3. c the NICE schizophrenia guidelines recommend that ECG and electrolyte tests are repeated after each dose escalation and at 6-monthly intervals

    4. d Bazett's correction formula is used in most automated ECG devices

    5. e drug-induced extension of the QTc interval to between 450 and 500 ms strongly predicts sudden cardiac death.

  2. 2 Risk factors for torsades de pointes include:

    1. a male gender

    2. b hypokalaemia

    3. c congenital long-QT syndrome

    4. d heart failure

    5. e hypomagnesaemia.

  3. 3 Modifiable risk factors for developing cardiovascular disease include:

    1. a old age

    2. b obesity

    3. c diabetes

    4. d male gender

    5. e sedentary lifestyle.

  4. 4 Screening tests for all psychiatric patients considered for an antipsychotic drug should include:

    1. a blood pressure measurement

    2. b glucose tolerance test

    3. c an ECG

    4. d an EEG

    5. e liver function tests.

Table 4 Psychotropics (excluding antipsychotics) and cytochrome P450 metabolising enzymes1

Cytochrome P450 (CYP) enzymes
CYP 1A2 CYP 2D6 CYP 2C9 CYP 2C19 CYP 3A4
Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor
TCAs
Maprotiline
Fluvoxamine
Methadone
TCAs
Fluoxetine
Fluvoxamine
Mianserin
Venlafaxine
Maprotiline
Bupropion
TCAs
Paroxetine
Fluoxetine
Norfluoxetine
Sertralinel
Fluoxetine TCAs
Citalopram
Moclobemide
Diazepam
Fluvoxamine
Fluoxetine
Sertraline (?)
TCAs
Sertraline
Fluoxetine
Venlafaxine
Carbamazepine
Alprazolam
Zolpidem
Fluvoxamine
Fluoxetine
Paroxetine
Sertraline
Nefazodone
Venlafaxine
Methadone

Table 5 Non-psychotropics and cytochrome P450 metabolising enzymes1

Cytochrome P450 (CYP) enzymes
CYP 1A2 CYP 2D6 CYP 2C9 CYP 2C19 CYP 3A4
Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor Substrate Inhibitor
Propranolol
Theophylline
Ciprofloxacin
Grapefruit
Encainide
Felainide
Codeine
Tramadol
Halofantrine
Chloroquine
Quinidine
Propafenone
Beta-blockers
Diclofenac
Ibuprofen
Tolbutamide
Naproxen
Phenytoin
Warfarin
Fluoxetine Hexabarbital
Omeprazole
Propranolol
Omeprazole Terfenadine
Quinidine
Diltiazem
Midazolam
Erythromycin
Clarithromycin
Troleandomy-cin
Ketoconazole
Itraconazole
Cimetidine
Indinavir
Ritonavir
Saquinavir
Grapefruit

MCQ answers

1 2 3 4
a F a F a F a T
b F b T b T b F
c F c T c T c T
d T d T d F d F
e F e T e T e T

Footnotes

This is the second of two articles on this topic. The first, which appeared in the previous issue of APT, discussed risk factors and mechanisms of antipsychotic-induced sudden death (Reference Abdelmawla and MitchellAbdelmawla & Mitchell, 2006).

References

Abdelmawla, N. & Mitchell, A. J. (2006) Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms. Advances in Psychiatric Treatment, 12, 3544.CrossRefGoogle Scholar
Abidi, S. & Bhaskara, S. M. (2003) From chlorpromazine to clozapine: antipsychotic adverse effects and the clinician's dilemma. Canadian Journal of Psychiatry, 48, 749755.CrossRefGoogle ScholarPubMed
Al-Khatib, S. M., Allen LaPointe, N. M., Kramer, J. M. et al (2003) What clinicians should know about the QT interval. JAMA, 289, 21202127.CrossRefGoogle ScholarPubMed
Allen LaPointe, N., Al-Khatib, S. M., Kramer, J. M. et al (2002) Deficits in knowledge related to the QT interval that could impact patients' safety. Journal of the American College of Cardiology, 39, 125A.CrossRefGoogle Scholar
Ames, D., Camm, J., Cook, P. et al (2002) Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. Encéphale: Revue de Psychiatrie Clinique, Biologique et Thérapeutique, 28, 552562.Google ScholarPubMed
Bateman, D. N., Good, A. M., Afshari, R. et al (2003) Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland. British Journal of Clinical Pharmacology, 55, 596603.CrossRefGoogle ScholarPubMed
Bazett, H. C. (1920) An analysis of the time relations of electrocardiograms. Heart, 7, 353367.Google Scholar
Botstein, P. (1993) Is QT interval prolongation harmful? A regulatory perspective. American Journal of Cardiology, 72, 50B52B.CrossRefGoogle ScholarPubMed
Committee for Proprietary Medicinal Products (1997) Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. London: European Agency for the Evaluation of Medicinal Products. http://www.emea.eu.int/pdfs/human/swp/098696en.pdf Google Scholar
Diaz, F. J. & de Leon, J. (2002) Excessive antipsychotic dosing in two US state hospitals. Journal of Clinical Psychiatry, 63, 9981003.CrossRefGoogle Scholar
Funk-Brentano, C. & Jaillon, P. (1993) Rate-corrected QT interval: techniques and limitations. American Journal of Cardiology, 72, 17B22B.CrossRefGoogle Scholar
Ganguly, R., Kotzan, J. A., Miller, L. S. et al (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry, 65, 13771388.CrossRefGoogle ScholarPubMed
Garson, A. (1993) How to measure the QT interval – what is normal? American Journal of Cardiology, 72, 14B16B.CrossRefGoogle Scholar
Glassman, A. H. & Bigger, J. T. Jr. (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158, 17741782.CrossRefGoogle ScholarPubMed
Griffiths, C. & Flanagan, R. J. (2005) Fatal poisoning with antipsychotic drugs, England and Wales 1993–2002. Psychopharmacology, 19, 667674.CrossRefGoogle ScholarPubMed
Harrington, M., Lelliott, P., Paton, C. et al (2002) The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin, 26, 414418.CrossRefGoogle Scholar
Hatta, K., Takahashi, T., Nakamura, H. et al (1999) Hypokalemia and agitation in acute psychotic patients. Psychiatric Resource, 86, 8588.CrossRefGoogle ScholarPubMed
Haw, C. & Stubbs, J. (2003) Combined antipsychotics for ‘difficult-to-manage’ and forensic patients with schizophrenia: reasons for prescribing and perceived benefits. Psychiatric Bulletin, 27, 449452.CrossRefGoogle Scholar
Hennessy, S., Bilker, W. B., Knauss, J. S. et al (2002) Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ, 325, 10701072.CrossRefGoogle ScholarPubMed
Ito, H., Koyama, A. & Higuchi, T. (2005) Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British Journal of Psychiatry, 187, 243247.CrossRefGoogle ScholarPubMed
Jusic, N. & Lader, M. (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry, 165, 787791.CrossRefGoogle ScholarPubMed
Kupfer, D. & Sartorius, N. (2002) The usefulness and use of second-generation antipsychotic medications. Current Opinion in Psychiatry, 15 (suppl. 1), S1S30.Google Scholar
Labellarte, M. J., Crosson, J. E. & Riddle, M. A. (2003) The relevance of prolonged QTC measurement to pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 642650.CrossRefGoogle ScholarPubMed
Lelliott, P., Paton, C., Harrington, M. et al (2002) The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26, 411414.CrossRefGoogle Scholar
Liperoti, R., Gambassi, G., Lapane, K. L. et al (2005) Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696701.CrossRefGoogle ScholarPubMed
Malik, M. & Camm, A. J. (2001) Evaluation of drug-induced QT interval prolongation. Drug Safety, 24, 323351.CrossRefGoogle ScholarPubMed
Marder, S. R., Essock, S. M., Miller, A. L. et al (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 13341349.CrossRefGoogle ScholarPubMed
McAllister-Williams, R. H. & Ferrier, I. N. (2002) Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry, 180, 485489.CrossRefGoogle ScholarPubMed
Medicines Control Agency & Committee on Safety of Medicines (2001) QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance, 27, 4.Google Scholar
Montanez, A., Ruskin, J. N., Hebert, P. R. et al (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of the prospective cohort studies. Archives of Internal Medicine, 164, 943948.CrossRefGoogle ScholarPubMed
National Institute for Clinical Excellence (2002) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE. http://www.nice.org.uk/page.aspx?o=42424 Google Scholar
O'Brien, P. & Oyebode, F. (2003) Psychotropic medication and the heart. Advances in Psychiatric Treatment, 9, 414423.CrossRefGoogle Scholar
Priori, S. G. (1998). Exploring the hidden danger of noncardiac drugs. Journal of Cardiovascular and Electrophysiology, 9, 11141116.CrossRefGoogle ScholarPubMed
Rautaharju, P. M., Zhou, S. H., Wong, S. et al (1992) Sex differences in the evolution of the electrocardiographic QT interval with age. Canadian Journal of Cardiology, 8, 690695.Google ScholarPubMed
Ray, W. A., Meredith, S., Thapa, P. B. et al (2001) Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 11611167.CrossRefGoogle ScholarPubMed
Royal Australian and New Zealand College of Psychiatrists (2005) Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. Melbourne: RANZCP. http://www.ranzcp.org/pdffiles/cpgs/Clinician%20version%20full%20schizophrenia.pdf Google Scholar
Royal College of Psychiatrists (1997) The Association between Antipsychotic Drugs and Sudden Death (Council Report CR57).Google Scholar
Royal College of Psychiatrists (2006) Consensus Statement on High-Dose Antipsychotic Medication (Council Report CR138). London: Royal College of Psychiatrists. In press.Google Scholar
Santos, A. B., Beliles, K. E. & Arana, G. W. (1998) Parenteral use of psychotropic agents. In Medical Psychiatric Practice (vol. 2) (eds Stoudemire, A. & Fogel, B. S.) Washington, DC: American Psychiatric Press.Google Scholar
Schweitzer, P. (1992) The values and limitations of the QT interval in clinical practice. American Heart Journal, 124, 11211126.CrossRefGoogle ScholarPubMed
Smith, A. L. & Book, W. M. (2004) Effects of non-cardiac drugs, electricity, poisons, and radiation on the heart. In Hurst's The Heart (eds Fuster, V., Alexander, R. W., O'Rourke, R. A. et al) (11th edn). New York: McGraw-Hill.Google Scholar
Taylor, D. M. (2003) Antipsychotics and QT prolongation. Acta Psychiatrica Scandinavia, 107, 8595.CrossRefGoogle ScholarPubMed
Taylor, D., Paton, C. & Kerwin, R. (eds) (2005) The Maudsley 2005–2006 Prescribing Guidelines (8th edn). London: Taylor & Francis.CrossRefGoogle Scholar
Thomas, S. H. L. & Ferrier, I. N. (2003) Antipsychotic drug-induced QT interval prolongation. In Cardiovascular Risk Associated with Schizophrenia and its Treatment (ed. Camm, J.) London: Galliard Healthcare Communications.Google Scholar
Vitola, J., Vukanovic, J. & Roden, D. (1998) Cisapride-induced torsades de pointes. Journal of Cardiovascular Electrophysiology, 9, 11091113.CrossRefGoogle ScholarPubMed
Waddington, J. L., Youssef, H. A. & Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325329.CrossRefGoogle ScholarPubMed
Warner, J. P., Gledhill, J. A., Connell, F. et al (1996) How well do psychiatric trainees interpret electrocardiographs. A cross-sectional survey Psychiatric Bulletin, 20, 651652.CrossRefGoogle Scholar
Welch, R. & Chue, P. (2000) Antipsychotic agents and QT changes. Journal of Psychiatry and Neuroscience, 25, 154160.Google ScholarPubMed
Wilkie, A., Preston, N. & Wesby, R. (2001) High dose neuroleptics – who gives them and why? Psychiatric Bulletin, 25, 179183.CrossRefGoogle Scholar
Figure 0

Table 1 Classification of antipsychotic medication in terms of risk of cardiac arrhythmias

Figure 1

Fig. 1 An ECG trace showing the QT interval.

Figure 2

Table 2 QTc intervals

Figure 3

Figure 4

Table 3 Antipsychotic drugs and cytochrome P450 metabolising enzymes1

Figure 5

Fig. 2 Clinician's guide to antipsychotic monitoring in relation to cardiovascular disease.

Figure 6

Table 4 Psychotropics (excluding antipsychotics) and cytochrome P450 metabolising enzymes1

Figure 7

Table 5 Non-psychotropics and cytochrome P450 metabolising enzymes1

Figure 8

MCQ answers

Submit a response

eLetters

No eLetters have been published for this article.
You have Access
23
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *